Biocon

The approval makes Biocon's pertuzumab the first biosimilar to receive EC marketing authorisation under the European Medicines Agency's (EMA) new tailored clinical approach

Updated On: 18 Nov 2026 | 9:23 AM IST

Biocon secures US FDA approval, Glenmark launches cancer generic, Mankind signs licensing agreement

Updated On: 16 Nov 2026 | 10:52 PM IST

Biocon also said it has secured a global settlement and licence agreement with Genentech, allowing Pebrilzo's earliest licensed US launch in 2028.

Updated On: 16 Nov 2026 | 10:00 AM IST

Biocon's Q2FY27 net profit fell 52 per cent to ₹41 crore as delayed shipments worth $20 million hit margins, while revenue rose 2 per cent to ₹4,389 crore.

Updated On: 04 Nov 2026 | 11:41 PM IST

The biosimilar to Johnson & Johnson's Stelara will be commercialised in nine additional markets, expanding Biocon's global reach in immunology

Updated On: 26 Oct 2026 | 9:49 AM IST

The deal allows Biocon to launch the biosimilar in the EU and the UK from the Q1 of 2027, and in the US from the Q3 of 2028

Updated On: 14 Oct 2026 | 11:00 PM IST

Biocon's Pertuzumab has received a positive EMA CHMP recommendation, becoming the first biosimilar to clear the agency's new tailored clinical development approach for HER2-positive breast cancer

Updated On: 21 Sep 2026 | 10:39 AM IST

According to data compiled by Bloomberg, around 16.6 million shares of Biocon changed hands on the BSE in a single pre-market block trade.

Updated On: 09 Sep 2026 | 10:28 AM IST

Stocks to watch today: Swiggy, Manipal Health, Biocon, L&T Finance, Crompton Greaves, RailTel Corporation, Sammaan Capital, EaseMyTrip, among others, will be in focus today.

Updated On: 19 Aug 2026 | 7:56 AM IST

Biocon Ltd on Tuesday said its subsidiary has received supplemental approval from the US health regulator for Yesintek prefilled autoinjector. Yesintek is indicated for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis. The company's subsidiary in the United States has received supplemental US Food and Drug Administration (USFDA) approval for Yesintek of strengths 45 mg/0.5 ml single-dose prefilled autoinjector and 90 mg/ml single-dose prefilled autoinjector, Biocon said in a regulatory filing. Yesintek was originally approved by the USFDA on November 29, 2024, it added. The Yesintek single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs, the company said. Yesintek is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients

Updated On: 18 Aug 2026 | 4:51 PM IST

MF holding grows over 100x in Diamond Power Infrastructure

Updated On: 17 Aug 2026 | 7:37 AM IST

Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating leverage and a favourable product mix

Updated On: 06 Aug 2026 | 11:04 PM IST

Q1FY27 company results: Firms including JK Lakshmi Cement, Power Grid Corporation of India, Berger Paints, and Bikaji Foods are also to release their April-June earnings today

Updated On: 05 Aug 2026 | 10:04 AM IST

: Biocon Ltd on Wednesday said it has received notice of compliance approval from Canadian health regulator for its Yesintek (ustekinumab) autoinjector, indicated for the treatment of moderate to severe plaque psoriasis. The company's subsidiary in Canada has received Notice of Compliance (NOC) approval for Yesintek (ustekinumab) Autoinjector 45 mg/0.05 mL and 90 mg/mL from Health Canada, Biocon Ltd said in a regulatory filing. Health Canada previously granted NOC for Yesintek (solution for subcutaneous injection) 45 mg/0.5ml (prefilled syringe and vial) and 90 mg/ml (prefilled syringe) and Yesintek I.V. (solution for intravenous infusion) 130 mg/26 mL (5mg/mL) in October 2025, it added. The availability of the Yesintek autoinjector provides patients with an option that the originator product does not offer in Canada, the company said . The new format will allow customised treatment approaches across care settings and patient needs, it added. Biocon said Yesintek is indicated for

Updated On: 29 Jul 2026 | 12:02 PM IST

Biocon shares climbed 6.5 per cent after reports of Viatris unit Mylan's planned stake sale, with analysts saying the move is a financial decision that removes a long-standing overhang

Updated On: 14 Jul 2026 | 11:19 PM IST

Mylan, part of global healthcare company Viatris, plans to sell up to 92 million shares in Biocon through a secondary offering valued at as much as Rs 34.81 billion

Updated On: 13 Jul 2026 | 8:05 PM IST

The team put together by the firm's founder may be just what the next decade demands

Updated On: 27 May 2026 | 11:48 PM IST

Chandan Taparia of Motilal Oswal decodes how to trade Nifty and Bank Nifty today; here are stock bets and strategy

Updated On: 13 May 2026 | 6:48 AM IST

Kiran Mazumdar-Shaw explained why she has chosen her niece, Claire, as her successor, outlining a five-year transition plan that will eventually see Claire take over as chairperson

Updated On: 08 May 2026 | 11:45 PM IST

Biocon is scouting for biosimilar in-licensing opportunities while banking on multiple FY27 product launches to drive growth, margins, and market expansion

Updated On: 08 May 2026 | 10:42 PM IST